Navigation Links
Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
Date:3/13/2009

Preclinical Rationale for Clinical Trial Presented at USCAP Meeting

SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the enrollment of the first patient in a Phase 2, multi-center clinical trial of R788 (fostamatinib disodium) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). The clinical trial's primary objective is to assess the efficacy of R788, an orally bio-available Syk kinase inhibitor, in patients suffering from this subset of non-Hodgkin's lymphoma that originates in the patient's T-cells. Prior studies have suggested increased expression of Syk at the cellular level in many of these patients with PTCL.

"Since we have seen that R788 shows clinical therapeutic benefit in certain types of B-cell lymphomas and that Syk kinase appears to play an important role in certain PTCLs, we believe that R788 may offer new hope to the 12-15% of non-Hodgkin's lymphoma patients with the T-cell variety," said Elliott Grossbard, M.D., executive vice president and chief medical officer of Rigel.

In general, patients with PTCL have a poorer prognosis and fewer treatment options than B-cell lymphoma patients. The standard treatment regimen for PTCL, known as CHOP, fails to provide adequate or durable responses in many patients. CHOP is a treatment regimen consisting of cyclophosphamide, hydroxydoxorubicin, vincristine (oncovin) and prednisone.

Pre-clinical Results Presented at USCAP Meeting

In a related matter, results of a pre-clinical study of R788 were presented in an oral session of the United States and Canadian Academy of Pathology annual meeting in Boston this week on March 9, 2009. The presentation, entitled, "An Orally Available Syk Tyrosine Kinase Inhibitor Induces Apoptosis
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
2. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
3. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
4. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
8. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
9. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
10. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
11. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... As of February, InControl Medical, LLC ... women. "Shipping thousands of our devices ... the hundreds of letters, emails and phone calls ... positively impacted by our technology," said Herschel ... recently released Apex, an over-the-counter solution for female ...
(Date:3/27/2015)... March 27, 2015  RXi Pharmaceuticals Corporation ... LLC, today announced that they have entered ... novel and proprietary sd-rxRNA® technology for use ... collaboration has the potential to result in ... treatments that could be a significant step ...
(Date:3/27/2015)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... on oncology with an emphasis on the treatment ... reporting of data from a single -center experience ... the Delcath Hepatic Delivery System (Melphalan/HDS) and other ... of Surgical Oncology (SSO) Annual Meeting 2015.  The ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
...   Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), ... president and chief executive officer of Pacira Pharmaceuticals, is scheduled ... Tuesday, September 20, 2011, at 11 a.m. EDT to be ... Center in New York City. Mr. Stack is expected to ...
... 2011 VIVUS, Inc. (NASDAQ: VVUS ) ... study in diabetics.  In the REVIVE-Diabetes study (TA-302), male ...  Dr. Irwin Goldstein, Director of Sexual Medicine at Alvarado ... study during the poster session at the 47th European ...
Cached Medicine Technology:Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference 2Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting 2Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting 3Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting 4
(Date:3/27/2015)... 27, 2015 When struck with the ... to know where to begin. The latest eBook ... accident attorney, offers accident victims a clear and concise ... to ensure their personal injury claim is seen through ... the first actions that should be taken immediately following ...
(Date:3/27/2015)... March 27, 2015 To address their number ... Super-Sod spent a year filming this video to explain the ... the shady environment it's often expected to thrive in, be ... plants need light to survive. Anytime a sun-loving plant is ... on a diet. Many homeowners try to amend this issue ...
(Date:3/27/2015)... Since September 2014, the country singer has ... after having been in retirement for a period of 13 ... to return to touring, and concert events have been booking ... likely sell out for the two shows recently scheduled for ... view the inventory of discounted Garth Brooks tickets for sale. ...
(Date:3/27/2015)... 2015 Smile Brands Inc. ( http://www.smilebrands.com ... support services to dental groups in the United States, ... Castle Dental office in Hendersonville, TN. , ... this new Castle Dental office provides families with a ... in comprehensive, quality dental care. Hendersonville marks the eleventh ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Yisrayl Hawkins, Pastor ... says the only way to live in Peace is through ... a new article published this week. , The article titled, ... state of mankind and how straying away from the original ... Yisrayl says the system that has been created in the ...
Breaking Medicine News(10 mins):Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:For Spring Turf Planting Season, Super-Sod Created a New How-To Video Entitled "Two Views on Shade and Turf" 2Health News:Garth Brooks Tickets for Omaha: BuyCheapTicketsToEvents.com Draws Customers by Discounting Prices on 2015 Tickets for Garth Brooks’ Tour Stops at CenturyLink Center 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3Health News:The World Does Not Have to Continue in Misery, Says Yisrayl Hawkins in New Article 2
... Denise Mann HealthDay Reporter , MONDAY, July ... juice or capsules for the treatment and prevention of ... antibiotics may be more effective even if they contribute ... are less effective in the prevention, but do not ...
... 26, 2011] Antibiotic overuse and resistance have emerged as ... outbreak of Clostridium difficile infections, which often result from ... physicians and pharmacists with an education campaign that reduced ... Clinical Infectious Diseases and now available ...
... 2011Better data are needed to evaluate access to care ... as older African Americans, and to assess the benefits ... health information technology and access to multilevel diabetes education ... Management , a peer-reviewed journal published by Mary Ann ...
... July 25 (HealthDay News) -- Hospitalized patients who are able ... satisfied with their care, but one-fifth are not given the ... The authors of the new study compiled information on the ... three-year period, and had the patients rate their sense of ...
... MONDAY, July 25 (HealthDay News) -- The varicella vaccine has nearly ... study shows. The vaccine, introduced in a one-dose form ... all age groups and by 97 percent in young people 20 ... Immunization and Respiratory Diseases. "This is one of our ...
... Southwestern Medical Center researchers have narrowed the potential drug ... tumors are driven by a different hormonal pathway than ... known to stimulate the growth of the disease, advanced ... actually is driven by a pathway that circumvents the ...
Cached Medicine News:Health News:Antibiotics Beat Cranberries at Fighting Urinary Tract Infections in Study 2Health News:Antibiotics Beat Cranberries at Fighting Urinary Tract Infections in Study 3Health News:Simple guidelines decreased unnecessary antibiotic use in Quebec, Canada 2Health News:New data-based strategies and treatment models can improve diabetes care for older African-Americans 2Health News:Spiritual Talks May Boost Patients' View of Hospital Care 2Health News:Chickenpox Vaccine May Wipe Out Related Deaths: Study 2Health News:Chickenpox Vaccine May Wipe Out Related Deaths: Study 3Health News:UT Southwestern scientists discover new pathway to potential therapies for advanced prostate cancer 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: